The LRP1-Mediated Endosomal Escape Enhancement Strategy proposes that therapeutic antibody delivery to the CNS can be optimized by targeting the low-density lipoprotein receptor-related protein 1 (LRP1) pathway while simultaneously engineering antibodies with pH-responsive endosomal escape mechanisms. Unlike FcRn-dependent transport which relies on passive transcytosis, this approach leverages LRP1's high-capacity apolipoprotein E (APOE)-mediated endocytic pathway at the blood-brain barrier. The strategy involves conjugating therapeutic antibodies to APOE-mimetic peptides or small molecule LRP1 ligands, facilitating receptor-mediated endocytosis into brain endothelial cells. The critical innovation lies in incorporating pH-sensitive fusogenic peptides or membrane-disrupting sequences that become activated in the acidic endosomal environment (pH 5.5-6.0), promoting antibody escape from endolysosomal degradation pathways. This dual mechanism addresses two major limitations of current CNS antibody delivery: insufficient BBB penetration and post-transcytotic lysosomal degradation.

The LRP1-Mediated Endosomal Escape Enhancement Strategy proposes that therapeutic antibody delivery to the CNS can be optimized by targeting the low-density lipoprotein receptor-related protein 1 (LRP1) pathway while simultaneously engineering antibodies with pH-responsive endosomal escape mechanisms. Unlike FcRn-dependent transport which relies on passive transcytosis, this approach leverages LRP1's high-capacity apolipoprotein E (APOE)-mediated endocytic pathway at the blood-brain barrier. The strategy involves conjugating therapeutic antibodies to APOE-mimetic peptides or small molecule LRP1 ligands, facilitating receptor-mediated endocytosis into brain endothelial cells. The critical innovation lies in incorporating pH-sensitive fusogenic peptides or membrane-disrupting sequences that become activated in the acidic endosomal environment (pH 5.5-6.0), promoting antibody escape from endolysosomal degradation pathways. This dual mechanism addresses two major limitations of current CNS antibody delivery: insufficient BBB penetration and post-transcytotic lysosomal degradation. The LRP1 receptor, highly expressed on brain capillary endothelium and involved in APOE-cholesterol clearance, provides a well-characterized transcytotic pathway with predictable kinetics. By modulating LDLR expression levels in brain endothelial cells through targeted gene therapy or pharmacological upregulation, the cholesterol transport machinery can be primed to enhance LRP1-mediated transcytosis efficiency. This approach transforms the typically degradative endosomal trafficking into a productive delivery pathway, potentially achieving 10-100 fold improvements in CNS antibody concentrations compared to passive diffusion or FcRn-dependent mechanisms. The strategy is particularly relevant for neurodegenerative diseases where amyloid-beta or tau-targeting antibodies require sustained CNS exposure.